MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group
Pediatric Blood & Cancer2017Vol. 64(11)
Citations Over TimeTop 10% of 2017 papers
Steven G. DuBois, Rajen Mody, Arlene Naranjo, Collin Van Ryn, Douglas Russ, Derek A. Oldridge, Susan G. Kreissman, David L. Baker, Marguerite T. Parisi, Barry L. Shulkin, Harrison X. Bai, Sharon J. Diskin, Vandana Batra, John M. Maris, Julie R. Park, Katherine K. Matthay, Gregory A. Yanik
Abstract
Patients with MIBG nonavid neuroblastoma have lower rates of adrenal primary tumors, bone metastasis, and catecholamine secretion. Despite being more likely to have MYCN-amplified tumors, these patients have superior outcomes compared with patients with MIBG avid disease.
Related Papers
- → Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies(2012)218 cited
- → Nanoscale spatial dependence of avidity in an IgG1 antibody(2021)25 cited
- → Impact of HIV Subtype on Performance of the Limiting Antigen-Avidity Enzyme Immunoassay, the Bio-Rad Avidity Assay, and the BED Capture Immunoassay in Rakai, Uganda(2013)36 cited
- → A competition assay for antibody avidity(1976)4 cited
- → Nanoscale spatial dependence of avidity in an IgG1 antibody(2019)1 cited